These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 35999119)

  • 21. Recirculant hyperthermic IntraVEsical chemotherapy (HIVEC) in intermediate-high-risk non-muscle-invasive bladder cancer.
    Sousa A; Piñeiro I; Rodríguez S; Aparici V; Monserrat V; Neira P; Carro E; Murias C; Uribarri C
    Int J Hyperthermia; 2016 Jun; 32(4):374-80. PubMed ID: 26915466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The efficacy of hyperthermic intravesical chemotherapy in high-risk non-muscle-invasive bladder cancer patients with BCG intolerance.
    Akbulut F; Pazir Y; Esmeray A; Erbin A; Ozgor F; Sarilar O
    Urologia; 2023 Nov; 90(4):631-635. PubMed ID: 37470319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quality of life and adverse events in patients with nonmuscle invasive bladder cancer receiving adjuvant treatment with BCG, MMC, or chemohyperthermia.
    González-Padilla DA; González-Díaz A; Guerrero-Ramos F; Rodríguez-Serrano A; García-Jarabo E; Corona-laPuerta M; Rodríguez-Antolín A; Villacampa-Aubá F
    Urol Oncol; 2021 Jan; 39(1):76.e9-76.e14. PubMed ID: 32753359
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical trial of high dose hyperthermic intravesical mitomycin C for intermediate and high-risk non-muscle invasive bladder cancer during BCG shortage.
    Grimberg DC; Dudinec J; Shah A; Inman BA
    Urol Oncol; 2021 Aug; 39(8):498.e13-498.e20. PubMed ID: 33485761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Efficacy and Safety of Hyperthermia Intravesical Chemotherapy in the Treatment of Non-Muscle-Invasive Bladder Cancer: A Meta-Analysis.
    Duan H; Deng Z; Zou J; Zhang G; Zou X; Xie T
    Urol Int; 2024; 108(4):322-333. PubMed ID: 38508149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Guérin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer.
    Zazzara M; Nazaraj A; Scarcia M; Cardo G; Carando R; Ludovico GM
    Urol Int; 2023; 107(1):64-71. PubMed ID: 34933307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravesical electromotive drug administration for non-muscle invasive bladder cancer.
    Jung JH; Gudeloglu A; Kiziloz H; Kuntz GM; Miller A; Konety BR; Dahm P
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011864. PubMed ID: 28898400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Multicenter Study of 2-year Outcomes Following Hyperthermia Therapy with Mitomycin C in Treating Non-Muscle Invasive Bladder Cancer: HIVEC-E.
    Tan WP; Plata Bello A; Garcia Alvarez C; Guerrero-Ramos F; González-Padilla DA; Nzeh C; Manuel de la Morena J; de Torres IGV; Hendricksen K; Díaz Goizueta FJ; Del Álamo JF; Chiancone F; Fedelini P; Poggio M; Porpiglia F; Gonzalo Rodríguez VC; Torres JM; Wilby D; Robinson R; Sousa-Escandón A; Mata JL; Pontones Moreno JL; Molina FD; Adriazola Semino MA; Stemberger AT; Escudero JC; Redorta JP; Tan WS
    Bladder Cancer; 2022; 8(4):379-393. PubMed ID: 38994184
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemoablation with Intensive Intravesical Mitomycin C Treatment: A New Approach for Non-muscle-invasive Bladder Cancer.
    Racioppi M; Di Gianfrancesco L; Ragonese M; Palermo G; Sacco E; Bassi P
    Eur Urol Oncol; 2019 Sep; 2(5):576-583. PubMed ID: 31411974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loco-regional deep hyperthermia combined with intravesical Mitomycin instillation reduces the recurrence of non-muscle invasive papillary bladder cancer.
    Wen YC; Lee LM; Lin YW; Syu SH; Lin KH; Fan YC; Lee HL; Lai BCH; Shih HJ
    Int J Hyperthermia; 2021; 38(1):1627-1632. PubMed ID: 34775895
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mitomycin C allergy after passive and device-assisted hyperthermia for non-muscle invasive bladder cancer treatment: A retrospective cohort from a high-volume center.
    González-Padilla DA; Subiela JD; González-Díaz A; Hernández-Arroyo M; García-Rojo E; Aumatell J; Burgos Revilla J; Rodríguez-Antolín A; Guerrero-Ramos F
    Urol Oncol; 2022 Jul; 40(7):345.e19-345.e23. PubMed ID: 35430137
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A multi-institutional retrospective study of hyperthermic plus intravesical chemotherapy versus intravesical chemotherapy treatment alone in intermediate and high risk nonmuscle-invasive bladder cancer.
    Ruan Q; Ding D; Wang B; He C; Ren X; Feng Z; Pang Z; Wang J; Zhang X; Tang H; Wang J; He Q; Lei Z; Liao Q; Luo J; Cui S
    Cancer Biol Med; 2021 Feb; 18(1):308-317. PubMed ID: 33628603
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301).
    Hayne D; Stockler M; McCombie SP; Chalasani V; Long A; Martin A; Sengupta S; Davis ID
    BMC Cancer; 2015 May; 15():432. PubMed ID: 26014129
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
    Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ;
    Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant intravesical therapy in intermediate-risk non-muscle-invasive bladder cancer.
    Laukhtina E; Gontero P; Babjuk M; Moschini M; Teoh JY; Rouprêt M; Trinh QD; Chlosta P; Nyirády P; Abufaraj M; Soria F; Klemm J; Bekku K; Matsukawa A; Shariat SF
    BJU Int; 2024 Oct; 134(4):644-651. PubMed ID: 38627025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reply to Fabio Campodonico, Francesca Mattioli, and Carlo Introini's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003.
    Tan WS; Kelly JD;
    Eur Urol; 2023 Jan; 83(1):e29-e30. PubMed ID: 36272948
    [No Abstract]   [Full Text] [Related]  

  • 37. Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial.
    Solsona E; Madero R; Chantada V; Fernandez JM; Zabala JA; Portillo JA; Alonso JM; Astobieta A; Unda M; Martinez-Piñeiro L; Rabadan M; Ojea A; Rodriguez-Molina J; Beardo P; Muntañola P; Gomez M; Montesinos M; Martinez Piñeiro JA;
    Eur Urol; 2015 Mar; 67(3):508-16. PubMed ID: 25301758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reply to Suman Sahoo, Abhishek Pandy, Swarnendu Mandal, Manoj Kumar Das, and Prasant Nayak's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003.
    Tan WS; Mustard C; Kelly JD;
    Eur Urol; 2023 Feb; 83(2):e48-e49. PubMed ID: 36456403
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment of High-grade Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial "NIMBUS".
    Grimm MO; van der Heijden AG; Colombel M; Muilwijk T; Martínez-Piñeiro L; Babjuk MM; Türkeri LN; Palou J; Patel A; Bjartell AS; Caris C; Schipper RG; Witjes WPJ;
    Eur Urol; 2020 Nov; 78(5):690-698. PubMed ID: 32446864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-Term Experience with Hyperthermic Chemotherapy (HIVEC) Using Mitomycin-C in Patients with Non-Muscle Invasive Bladder Cancer in Spain.
    Plata A; Guerrero-Ramos F; Garcia C; González-Díaz A; Gonzalez-Valcárcel I; de la Morena JM; Díaz-Goizueta FJ; Del Álamo JF; Gonzalo V; Montero J; Sousa-Escandón A; León J; Pontones JL; Delgado F; Adriazola M; Pascual Á; Calleja J; Ruano A; Martínez-Piñeiro L; Angulo JC
    J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.